Defective recombinant adenoviruses expressing cytokines for antitumor treatment
AssigneesCentre National De La Recherche Scientifique, Institut Gustave Roussy
InventorsHédi Mohamed Haddada, Thierry Ragot, Michel Perricaudet
Life of this patent
Estimating the term…
Abstract
A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.
Claims9
A method for treating a tumor in patients in need of such treatment, said method comprising injecting an effective amount of a pharmaceutical composition into said tumor, wherein said pharmaceutical composition comprises:
- (a) a replication-defective adenoviral vector comprising a nucleic acid sequence coding for a cytokine selected from the group consisting of an interleukin 2 and gamma interferon under the control of a promoter selected from the group consisting of a promoter contained in the long terminal repeat of a Rous Sarcoma virus and a promoter of an IE gene of cytomegalovirus;
- and
- (b) a pharmaceutically acceptable vehicle.
A method for delivering a cytokine to a tumor, to treat a patient, said method comprising injecting an effective amount of a composition into said tumor, wherein said composition comprises:
- (a) a replication-defective adenoviral vector lacking the E1A, E1B and E3 regions of an adenovirus;
- and comprising a nucleic acid sequence coding for a cytokine selected from the group consisting of interleukin-2 and gamma interferon, under the control of a promoter selected from the group consisting of a promoter contained in the long terminal repeat of a Rous Sarcoma Virus and a promoter of an IE gene of cytomegalovirus;
- and
- (b) a pharmaceutically acceptable vehicle.
Dependencies are inferred from the claim text.